LBA45 Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon …

R Salazar, S Tafuto, M Krogh, A Teule… - Annals of …, 2022 - annalsofoncology.org
Background STZ-5FU and everolimus are frontline treatments in patients (pts) with
advanced and progressive pancreatic panNETs. Switching between both upon progression
is a common strategy, but the best sequence is not yet well established. Methods SEQTOR
trial aims to compare the progression-free survival rate to 1st treatment (PFS1) at 12 months
(m) in STZ-based CT vs Everolimus. Secondary endpoints included objective response rate
(ORR), clinical benefit rate (CBR), median PFS1 (mPFS1) and PFS to 2nd treatment (PFS2) …
以上显示的是最相近的搜索结果。 查看全部搜索结果